SavedAdd your journal

Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2017 / Cilt: 63 - Sayı: 4

Gabapentinoids in penitentiaries: An abuse and addiction research

İlker İLHANLI
Murat GÜL
Necip GÜDER
Pages
318–328
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that 2% of the participants used pregabalin and gabapentin simultaneously, while 25.2% of them used multiple drugs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to examine the abuse and addiction of gabapentinoids in penal institutions.Patients and methods: Between September 2014 and November 2014, a total of 1,639 participants were administered an electronic questionnaire investigating the drug use and addiction.
📊
Key Findings & Data:The questionnaire was requested to be asked and filled by the officers in charge for all voluntary convicts and prisoners in all penitentiaries throughout Turkey.Results: The rate of answering the questions varied between 20.5% and 100%.
💡
Conclusion & Impact:It was found that 2% of the participants used pregabalin and gabapentin simultaneously, while 25.2% of them used multiple drugs.
🔬Design:Survey & Empirical Study
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to examine the abuse and addiction of gabapentinoids in penal institutions.Patients and methods: Between September 2014 and November 2014, a total of 1,639 participants were administered an electronic questionnaire investigating the drug use and addiction. The questionnaire was requested to be asked and filled by the officers in charge for all voluntary convicts and prisoners in all penitentiaries throughout Turkey.Results: The rate of answering the questions varied between 20.5% and 100%. It was found that 2% of the participants used pregabalin and gabapentin simultaneously, while 25.2% of them used multiple drugs. The usage rate of pregabalin and gabapentin was higher in some penitentiaries, compared to the normal population. There was a significant positive correlation between the use of gabapentinoids and multiple drugs and alcohol and drug addiction, various withdrawal symptoms, the number of going to the infirmary, and the number of referral to the hospital (p

🔖

Cite This Article

İLHANLI, İ., GÜL, M., GÜDER, N. (2022). Gabapentinoids in penitentiaries: An abuse and addiction research. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 63 - Sayı: 4, 318–328. https://ajindex.com/articles/628608

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002;45:171-90
  2. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76
  3. Kelly KM. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 1998;38:139-44
  4. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93
  5. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3- isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810:93-9
  6. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36
  7. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10
  8. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H] glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93:191-6
  9. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:1-41
  10. Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL. Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1008 (pregabalin) and gabapentin in rats with maximal electroshock. Epilepsia 1997;38:35
  11. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-9
  12. Oulis P, Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. CNS Neurosci Ther 2010;16:45-50
  13. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8:177-89
  14. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44
  15. Schwan S, Sundström